Management of fetal and neonatal alloimmune thrombocytopenia

Détails

ID Serval
serval:BIB_A3FFD330D009
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Management of fetal and neonatal alloimmune thrombocytopenia
Périodique
Biology of the Neonate
Auteur⸱e⸱s
Forestier  F., Hohlfeld  P.
ISSN
0006-3126 (Print)
Statut éditorial
Publié
Date de publication
12/1998
Volume
74
Numéro
6
Pages
395-401
Notes
Journal Article
Review --- Old month value: Dec
Résumé
Fetal and neonatal thrombocytopenia can be induced by a maternal alloimmunization against fetal platelet antigens. Alloimmune thrombocytopenia occurs with an incidence of 1/1,000 livebirths and may present either with evidence of damage from a prenatal hemorrhage such as porencephaly or intrauterine death, or with active life-threatening bleeding during the neonatal period. It is due to the destruction of fetal platelets by alloantibodies reacting on specific antigenic sites. In Caucasians, the human platelet antigen 1a (HPA-1a) is the most frequently involved in alloimmune thrombocytopenias, accounting for 80-90% of the cases. Anti-HPA-5b is responsible for a further 5-15% of the cases. This article reviews the clinical aspects, the biological diagnosis and the management, including prenatal sampling and maternal therapy.
Mots-clé
Antigens, Human Platelet/immunology Blood Platelets/immunology Female Fetal Diseases/*therapy Humans Infant, Newborn Isoantigens/immunology Pregnancy Thrombocytopenia/*immunology/*therapy
Pubmed
Web of science
Création de la notice
25/01/2008 11:12
Dernière modification de la notice
20/08/2019 15:09
Données d'usage